LLY

1,070.14

+0.75%↑

JNJ

208.45

-0.23%↓

ABBV

226.91

+1.23%↑

UNH

333.8

+2.13%↑

AZN

91.77

+0.79%↑

LLY

1,070.14

+0.75%↑

JNJ

208.45

-0.23%↓

ABBV

226.91

+1.23%↑

UNH

333.8

+2.13%↑

AZN

91.77

+0.79%↑

LLY

1,070.14

+0.75%↑

JNJ

208.45

-0.23%↓

ABBV

226.91

+1.23%↑

UNH

333.8

+2.13%↑

AZN

91.77

+0.79%↑

LLY

1,070.14

+0.75%↑

JNJ

208.45

-0.23%↓

ABBV

226.91

+1.23%↑

UNH

333.8

+2.13%↑

AZN

91.77

+0.79%↑

LLY

1,070.14

+0.75%↑

JNJ

208.45

-0.23%↓

ABBV

226.91

+1.23%↑

UNH

333.8

+2.13%↑

AZN

91.77

+0.79%↑

Search

PerkinElmer Inc

Open

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

51.072

76.798

EPS

1.18

Dividendrendement

0.28

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+14.93% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.28%

2.37%

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

223M

12B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

23%

77%

43 / 374 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 dec 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec 2025, 23:51 UTC

Winsten

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec 2025, 23:39 UTC

Belangrijke Marktbewegers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec 2025, 21:40 UTC

Winsten

Nike Sales Tick Up, But China Weakness Persists

18 dec 2025, 23:45 UTC

Marktinformatie

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec 2025, 23:37 UTC

Marktinformatie
Winsten

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec 2025, 22:58 UTC

Acquisities, Fusies, Overnames

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec 2025, 22:56 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec 2025, 22:55 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:59 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 dec 2025, 21:35 UTC

Winsten

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec 2025, 21:31 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev Down 17% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q EPS 53c >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Apparel Rev $3.91B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Equipment Rev $550M >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q N Amer Rev $5.63B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Footwear Rev $7.66B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev $1.42B >NKE

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

14.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.22 USD  14.93%

Hoogste 123 USD

Laagste 100 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Sentiment

By Acuity

43 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat